Development of LONASEN<sup>Ⓡ</sup>Tape, the world’s first transdermal antipsychotic drug

DOI Web Site 2 References
  • Tanaka Masayasu
    Technology Research & Development Division, Formulation Research & Development Laboratories, Sumitomo Pharma Co., Ltd.

Bibliographic Information

Other Title
  • 世界初の抗精神病薬の経皮吸収型製剤ロナセン<sup>Ⓡ</sup>テープの開発

Abstract

Blonanserin is an atypical antipsychotic drug with dopamine D2, D3 and serotonin 5-HT2A receptor antagonism. We jointly developed the world’s first antipsychotic transdermal patch containing blonanserin as active pharmaceutical ingredient with Nitto Denko Corporation, and started domestic sales in September 2019. There are three technical hurdles in formulation development of transdermal patch： skin permeability, skin irritation, and adhesiveness. We overcame these technical hurdles and succeeded in developing the formulation of LONASENⓇ Tape. Here, along with detail report on the formulation development, the background to development and the results of clinical studies are also described.

Journal

  • Drug Delivery System

    Drug Delivery System 37 (5), 438-443, 2022-11-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top